Immediate Impact
56 standout
Citing Papers
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Latest advances in hepatocellular carcinoma management and prevention through advanced technologies
2024 Standout
Works of Bolag Altan being referenced
Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
2017
Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Bolag Altan | 590 | 386 | 98 | 304 | 35 | 989 | |
| Joerg Schwock | 397 | 285 | 118 | 213 | 35 | 903 | |
| Wendy Prime | 657 | 358 | 100 | 276 | 24 | 1.1k | |
| Nadire Duru | 785 | 400 | 92 | 513 | 26 | 1.3k | |
| Christos Valavanis | 643 | 239 | 162 | 219 | 38 | 1.1k | |
| Morag Seywright | 478 | 316 | 108 | 239 | 39 | 934 | |
| Marion T. Weigel | 470 | 324 | 108 | 265 | 27 | 1.0k | |
| A. Craig Lockhart | 514 | 465 | 98 | 229 | 49 | 1.0k | |
| Monika Bauden | 515 | 622 | 147 | 303 | 31 | 1.1k | |
| Lin Guo | 712 | 327 | 93 | 434 | 69 | 1.2k | |
| Nicole E. Willmarth | 664 | 489 | 56 | 385 | 23 | 1.2k |
All Works
Loading papers...